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Abstract
Diabetic peripheral neuropathy (DPN) is one of the most widespread and disabling
neurological conditions, accounting for half of all neuropathy cases worldwide. Despite
its high prevalence, no approved disease modifying therapies exist. There is now a
growing body of evidence that DPN secondary to type 1 diabetes mellitus (T1DM) and
type 2 diabetes mellitus (T2DM) represents different disease processes, with T2DM
DPN best understood within the context of metabolic syndrome rather than hypergly-
cemia. In this review, we highlight currently understood mechanisms of DPN, along
with their corresponding potential therapeutic targets. We frame this discussion within
a practical overview of how the field evolved from initial human observations to
murine pathomechanistic and therapeutic models into ongoing and human clinical tri-
als, with particular emphasis on T2DM DPN and metabolic syndrome.
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1 | INTRODUCTION
Diabetic peripheral neuropathy (DPN) is a length-dependent sensory pre-
dominant axonal neuropathy that often first manifests with dysesthesias,
pain, numbness, or imbalance. DPN has a prevalence ranging from 10% to
50% for both type 1 diabetes (T1DM) and type 2 diabetes (T2DM). The
DPN annual cost, including complications, exceeds $10 billion in the United
States alone.1 DPN leads to reduced quality of life due to increased pain,
falls, lower limb ulcers, and amputations. While glycemic control has been
shown to be effective in DPN associated with T1DM, it carries only a mod-
est effect in DPN associated with T2DM.2,3 Furthermore, while neuropa-
thy associated with T1DM and T2DM has classically been categorized
together, we now know that the two are largely different disease pro-
cesses.4,5 Despite recent clinical testing of contemporary drugs (Table 1)
and decades of research on a massive global health burden, no approved
disease-modifying therapies exist. Previous drug trials focused on antioxi-
dants12-18; lipid lowering fibrates16,19; aldose reductase inhibitors20-23;
neurotrophic factors24-26; GABA analogues27; cellular metabolism
agonists28-31; and vasodilators13,32 and have had limited efficacy in treating
DPN associated with T1DM and T2DM.33,34 Nevertheless, with our
increased understanding of DPN pathogenesis, there is general optimism
that new therapies for DPN are on the horizon. In this review, we focus on
our current understanding of DPN pathogenesis and potential therapeutic
targets, with a particular focus on DPN in the setting of T2DM and meta-
bolic syndrome (MetS). We highlight how initial clinical observations in
patients led to the development of murine models of T2DM and prediabe-
tes, which guided our understanding of pathomechanisms and potential
therapies. These studies inform ongoing and future clinical trials and our
approach to identifying disease modifying therapies.
2 | CRYPTOGENIC SENSORY PERIPHERAL
NEUROPATHY AND METABOLIC SYNDROME
Clinicians caring for patients with cryptogenic sensory peripheral neu-
ropathy (CSPN) in the 1990s observed that many patients without
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diabetes carried features similar to patients with diabetes, particularly
in regards to obesity and MetS. Since then, seven international
population-based studies—five cross-sectional and two-longitudinal—
spanning the United States, Europe, and China have shown obesity to
be the second most significant metabolic risk factor for neuropathy
after diabetes.35-40 Waist circumference and diabetes are the most
significant risk factors for neuropathy,36 with waist circumference
associating with the greatest number of neuropathy outcome mea-
sures.37 In addition, the likelihood of symptomatic CSPN rises as the
number of MetS features increases. Furthermore, in patients with
established DPN, obesity and hyperlipidemia accelerate the rate of
DPN development.41
Obesity is the main driver of MetS, producing a chronic state of
low-grade metabolic inflammation and an elevated level of long-chain
fatty acids that places undue burden on the peripheral nervous sys-
tem.35 In line with such findings, CSPN in the setting of obesity and
MetS is now classified as obesity- or MetS-associated neuropathy.
Dyslipidemia, a component of the MetS criteria, warrants particular
attention. Hypertriglyceridemia independently associates with the
development of CSPN,42 decreased sural nerve myelinated fiber
density,43 loss of intraepidermal nerve fiber density (IENFD),41 the
progression of established DPN,43 and the likelihood of lower limb
amputations.44 Conversely, lipid lowering therapy reduces the likeli-
hood of the long-term development of DPN,45,46 as well as the risk of
lower limb amputation.47
In addition, impaired fasting glucose (IFG) and impaired glucose
tolerance (IGT), which form part of the MetS diagnostic criteria, inde-
pendently associate with the development of CSPN, and warrant dis-
cussion. Cross-sectional data from the MONICA/KORA study showed
a neuropathy prevalence of 8.7% and 4.2% in patients with IGT and
IFG, respectively.48 The PROMISE longitudinal study showed that
prediabetic patients (IGT or IFG) carried the same prevalence of neu-
ropathy at 3-year follow-up (50%) as diabetics.49 In addition, when
looking at patients with established CSPN, the prevalence of IFG can
be as high as 56%.50
Somatic small unmyelinated C fibers, quantified through IENFD,
are particularly sensitive at capturing early DPN. Equally important is
the capacity of these somatic small fibers to regenerate, and thus to
serve as primary outcome measures for clinical trials.51 Also, corneal
confocal microscopy is a rapid, validated, non-invasive and in vivo
measure of small fiber function in diabetic neuropathy,52 which has
comparable accuracy to IENFD.53 Corneal confocal microscopy also
correlates with functional measures of neuropathy severity54 and
tracks improvement in diabetic patients after simultaneous pancreas-
kidney transplant.55 Thermal perception threshold (TT) testing is a
third validated and sensitive modality that captures diabetic small
fiber neuropathy quite well,56 and can also be used to distinguish
healthy patients from those with small fiber neuropathy.57 However,
lack of consensus on stimulus application, location, and sensations
tested hinders it more widespread adoption.58
3 | DYSLIPIDEMIA, BIOENERGETICS, AND
INFLAMMATION
3.1 | Murine models
In light of the clear clinical association between MetS and CSPN,
murine models were developed with the aim of understanding
pathomechanisms and developing concordant therapeutic interven-
tions for patients with DPN. In vitro, in vivo, and clinical studies
focused on mechanisms underlying the pathogenic role of
TABLE 1 Drug trials on peripheral neuropathy associated with T1DM and T2DM from 2010 to 2020
Drug
Disease or
pain modifying Mechanism of action
Diabetes
type




Pain Inhibits neurogenic inflammation
from peripheral nociceptive nerve
terminals
T2DM Improved tactile and mechanical
pain perception in painful DPN
6
Botulin toxin (BTX-A) Pain Potent neurotoxin, used in
treatment of dystonia, muscle
hyperactivity and glandular
hyperactivity. BTX-A may have
analgesic properties.







Disease Increases blood circulation T2DM No improvement 8
L-arginine Disease Substrate for nitric oxide synthesis
to improve microcirculation







T2DM Improved vibration perception
threshold, reduced neuropathic
symptoms, and pain disability
index.
10
Benfotiamine Disease Modulates advanced glycation end
products.
T1DM No effect on peripheral nerve
function
11
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hyperlipidemia and hyperglycemia on neuropathy. Juvenile genetic
murine models of prediabetes and T2DM arose, illustrating that
hyperglycemia was not the only driver of peripheral neuropathy.59,60
Murine models of T2DM, including leptin (ob/ob) and leptin receptor
(db/db) knockout models, are used to identify molecular pathways that
underlie neuropathy pathogenesis and are conserved between murine
models and humans.61 In addition, C57BL/6J diet-induced murine
models now exist, in which a lard-based, high-fat diet (HFD) chow,
consisting of elevated levels of long-chain fatty acids, induces predia-
betes and neuropathy.62,63 The HFD-fed C57BL/6J mice exposed to
low-dose streptozotocin serve as models for T2DM.64 All of these
murine models display neuropathic features, with increased thermal
latency, reduced nerve conduction velocity, and IENFD loss.
3.2 | Mitochondria and bioenergetics
Numerous studies explored the effect of T2DM and MetS, particularly
dyslipidemia, on the mitochondrion and bioenergetics in sensory neu-
rons and the peripheral nerves (Figure 1). Disorders of fission, fusion,
oxidative phosphorylation, and mitochondrial trafficking, among
others, are altered in diabetes, prediabetes, and dyslipidemia.65 Dys-
lipidemia mediates changes in complex lipid synthesis, which then
alters mitochondrial size, morphology, and motility.66 Palmitate and
stearate, for example, increase mitochondrial circularity and size,
probably due to mitochondrial dysfunction, swelling, and loss of inner
mitochondrial membrane structure.66 Although hyperglycemia has no
effect on mitochondrial trafficking in sensory neurons, increased con-
centrations of long-chain fatty acids impair mitochondrial trafficking
and alter mitochondrial bioenergetics experimentally.67 Palmitate, a
long-chain saturated fatty acid (SFA), lowers the number and velocity
of motile mitochondria and depolarizes mitochondria.68 Palmitate also
induces an increased rate of ATP turnover and basal respiration. Not
unlike sensory neurons, Schwann cells also show pathogenic changes
in response to dyslipidemia. Schwann cells increase the expression of
medium to long-chain acylcarnitines in response to long-chain fatty
acid overexposure, which in turn, induces peripheral nerve injury.69 In
parallel, sciatic nerves from HFD and HFD-STZ mice contain elevated
levels of palmitate and stearate in complex lipids such as triglycerides
and phospholipids.70 Transcriptomic and lipidomic analyses on those
samples showed abnormal nerve-lipid signaling, with samples showing
increased expression of diacylglycerol acyltransferase 2 (DGAT2), the
enzyme involved in the last step of triglyceride synthesis. This finding
was corroborated with sural nerves from dyslipidemic DPN patients.70
Of note, mitochondrial alterations also appear in intraepidermal nerve
fiber samples from human subjects with DPN.71 Mitochondria slarger
volumes at both distal thigh and distal leg sites in DPN patients rela-
tive to healthy controls, and also show a length dependent gradient,
with distal leg nerves showing larger mitochondrial volume than distal
thigh nerves. An earlier study also showed mitochondrial derange-
ments in skin sections from 32 patients with small fiber neuropathy, in
which mitochondrial respiratory chain complex IV (OXPHOS)
F IGURE 1 Pathogenic mitochondrial and inflammatory pathways associated with T2DM and dyslipidemia. SFAs associated with dyslipidemia
and T2DM drive acylcarnitine and triglyceride formation in sensory neurons and peripheral nerves. Excess levels of acylcarnitine lead to increased
mitochondrial dysfunction and apoptotic fission that may underlie T2DM DPN development. Dyslipidemia also causes an elevation in oxidized
LDL (ox-LDL) and advanced glycation end-product LDL (AGE-LDL) that trigger pro-inflammatory signals including TNF-α, IL-6, and COX-2,
perturbing mitochondrial function. Similarly, LDL is metabolized intracellularly into FFAs that increase ROS and initiate mitochondrial dysfunction
and apoptosis. In addition, nuclear transcription factors regulate pro-inflammatory signals (NF-κB pathway) and FFA β-oxidation (PGC-1α, PPARγ,
and LXR). Modulation of transcriptional regulation, fatty acid composition, or inflammatory pathways may offer therapeutic targets for the
treatment of T2DM DPN. DPN, diabetic peripheral neuropathy; FFA, free fatty acid; SFAs, saturated fatty acids
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fluorescence was reduced, despite preserved intraepidermal nerve
fibers.72 In addition, the normal co-localization of OXPHOS within
intraepidermal and subpapillary dermal axons was also lost.
3.3 | Substrate transport and uptake
Transport and substrate uptake is also dysregulated in the setting of
substrate overload. Free fatty acids (FFAs) are normally β-oxidized to
generate NADH and FADH2 in Schwann cells, dorsal root ganglion
sensory neurons, and axons. Of note, β-oxidation in Schwann cells
requires the transport of long-chain FFAs across cell membranes. Sub-
sequent to their uptake, FFAs are β-oxidized to produce acetyl-CoA,
which is then shuttled to the tricarboxylic acid cycle for the genera-
tion of NADH and FADH2. In T2DM, a dyslipidemic state creates FFA
substrate overload, which saturates the Schwann cell transport sys-
tem and causes an accumulation of acylcarnitines.69 Schwann cells
transfer accumulating acylcarnitines to sensory neurons causing axo-
nal degeneration and mitochondrial dysfunction.
Peroxisome proliferator-activated receptors (PPARs) are also
highly dysregulated in T2DM. PPARs are a superfamily of ligand-
activated transcription factors of nuclear hormone receptors that per-
form multiple physiological functions. The PPAR-γ subclass causes
enhanced glucose metabolism and insulin sensitization. Furthermore,
the PPAR-γ coactivator-1α (PGC-1α) is a transcriptional co-activator
and a master regulator for mitochondrial biogenesis in many tissues,
including peripheral nerve, and regulates expression of proteins
responsible for fatty acid uptake, particularly the fatty acid translocase
CD36.73-75 Also, liver X receptor (LXR) activation in murine neuropa-
thy models is central to the reduction of endoplasmic reticulum stress
and restoration of myelin lipid composition.76,77 LXRs are ligand-
activated nuclear transcription factors highly linked to PPARs.
3.4 | Dyslipidemia and inflammation
The interplay of dyslipidemia and inflammation serves as another focus
of research interest in our laboratory and that of others. In the setting
of substrate overload, oxidative phosphorylation fails, ATP production
declines, reactive oxygen species (ROS) arise, and low density lipopro-
teins are oxidized, triggering mitochondrial dysfunction78,79 (Figure 1).
Long-chain fatty acids penetrate the blood-nerve barrier, trigger neuro-
genic inflammation, and attract innate and adaptive cells, a finding cor-
roborated with increased expression of TNF-α and IL-6 in DPN animal
models.80 Neuronal oxidative stress triggers a cascade of downstream
cytokine and chemokine production of pro-inflammatory agents, while
also producing a feed-forward loop of injury.81 The generation of oxi-
dized cholesterol (oxysterol) induces tissue injury82 by binding to the
following 3 receptors: oxidized LDL receptor 1 (LOX1), a type II mem-
brane protein located in endothelial cells63; toll-like receptor 4 (TLR4), a
pattern-recognition receptor that initiates inflammatory and immune
responses83; and the receptor for advanced glycation end products
(RAGE), a receptor expressed in endothelial and Schwann cells which
contributes to vascular injury in DPN.84 In the db/db mouse model,
multiple immune molecules are upregulated in both the early and later
stages of disease.85 Inflammatory dysregulation occurs as early as
5 weeks of age in ob/ob and db/db mouse models.59,60,86 In addition,
toll-like receptor signaling influences the early development of DPN in
sensory neurons.87 Several inflammatory markers increase in T2DM,
including interleukin-6, sialic acid, plasminogen activator inhibitor-1,
fibrinogen, and C-reactive protein.88
Despite the complexity of the inflammatory process, NF-κB path-
way activation is a shared pathway. NF-κB functions as a redox-
sensitive transcription factor that is activated by hyperglycemia, oxi-
dative stress, and pro-inflammatory cytokines.88 It modulates multiple
downstream inflammatory genes, notably cyclooxygenase-2 (COX-2).
Of the acute phase cytokines modulated by the NF-κB pathway,
tumor necrosis factor α (TNF-α) warrants particular attention, as it
induces COX-2 overexpression, which, in turn, induces inflammatory
changes that lead to DPN.89 Furthermore, the heat shock chaperone
proteins (HSP) 70 and 90, responsible for protein refolding and regu-
lating proteostasis, as well as cellular protection from oxidative stress,
inflammation, and apoptosis, are a potential mechanistic target in
DPN. HSPs upregulate the NF-κB pathway, TNF-α, and IL-6 by bind-
ing with high affinity to the plasma membrane.90 These chaperones
can also improve neural mitochondrial bioenergetics and improve oxi-
dant capacity.91
3.5 | Dyslipidemic and inflammatory therapeutic
targets
In light of the above work on DPN pathomechanisms in murine
models, investigators explored potential therapeutic targets through
dietary reversal, unsaturated fatty acid dietary intervention, and anti-
inflammatory modulation (Figure 2). Dietary reversal in HFD mice is a
natural focus. HFD mice switched to a standard chow diet for
4 weeks demonstrate normalization of neuropathy, as well as
improved insulin sensitivity, increased weight loss, and restoration of
LDL and oxidative LDL levels.62 In a separate study evaluating the sci-
atic nerves of HFD and HFD-STZ mice, dietary reversal from a HFD
to a standard chow for 8 weeks lowers levels of pathogenic palmitate
and stearate in sciatic nerves.70 The introduction of mono- and poly-
unsaturated fatty acids also prevents peripheral neuropathy and
restores IENFD in mice fed a HFD rich in long-chain SFAs.66 A mix-
ture of oleate, a monounsaturated fatty acid (MUFA), and palmitate at
a 2:1 M ratio prevents palmitate-induced impairment of mitochondrial
transport.66,68 Increasing the ratio of n-3 to n-6 polyunsaturated fatty
acids also decreases diabetic complications in T2DM adults.92-94 Ole-
ate prevents mitochondrial depolarization, preserves intracellular ATP
levels, and reduces caspase activation by promoting lipid droplet
(LD) formation, and thus prevents palmitate-induced apoptosis.65,95 In
response to menhaden (fish) oil (rich in n-3 polyunsaturated fats),
HFD-STZ mice normalize motor and sensory nerve conduction veloci-
ties as well as thermal responsiveness.96 Combinatorial therapies also
provide promising therapeutic options. A diet rich in omega-3
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polyunsaturated fats alone or in combination with α-lipoic acid and/or
enalapril improves DPN in HFD-STZ mice as compared to untreated
animals.97 Additionally, pioglitazone, an agonist of PPAR-γ that
reduces plasma levels of FFAs, improves DPN in the T2DM db/db
mouse.98
As for inflammatory therapeutic avenues, the NF-κB pathway has
emerged as a natural target. Polyunsaturated fatty acids inhibit NF-κB
activation and nuclear translocation.99,100 In the previously cited
study that showed inflammatory dysregulation as early as 5 weeks in
ob/ob and db/db mice, pioglitazone and acipimox, both lipid lowering
agents, improved peripheral nerve metrics.59 COX-2 selective inhibi-
tion or gene inactivation prevents large and small nerve fiber dysfunc-
tion in murine models.89 Interleukin-6 (IL-6) improves motor and
sensory nerve conduction velocities101102 and corrects thermal
nociception and tactile allodynia, while increasing nerve blood
flow103,104.105 Finally, with regards to heat shock chaperone proteins,
modulation of Hsp70 and Hsp90 with small molecules improves DPN
in T1DM animal models.91,106
4 | CURRENT STATE OF HUMAN CLINICAL
TRIALS AND THE ROAD AHEAD
In light of our evolved understanding of DPN pathomechanisms and
the promise of new therapeutic targets, human clinical trials have
emerged to address the potential role of dietary restriction, exercise,
reduction in sedentary lifestyle, and bariatric surgery in the reversal and
prevention of DPN. In addition, we highlight two ongoing drug trials,
although disease-modifying drug therapeutics remains in its infancy.
The Look Ahead trial showed that intensive lifestyle intervention
resulted in improvement of self-reported metrics of DPN, as mea-
sured per the Michigan Neuropathy Severity Index, and per light
touch sensation on physical exam.107 Three non-randomized trials
have demonstrated the efficacy of exercise as a disease modifying
intervention for patients with MetS, using IENFD as the primary out-
come measure. The first showed improvement in 32 patients with
impaired glucose tolerance as measured at 12 months.108 The second
showed improvement in the regenerative capacity of small fibers in
36 patients with diabetes or MetS at 4 months after start of interven-
tion.109 The third showed improvement in 17 DPN patients at
10 weeks after intervention.110 It is worth noting that such improve-
ments occurred even in the absence of significant weight loss. One
randomized trial for patients with T1DM and T2DM DPN demon-
strated improved nerve conduction study parameters and vibration
perception thresholds after a 4-year aerobic exercise regimen,
although the trial did not separate T1DM from T2DM patients nor did
it designate IENFD, the current gold standard, as the primary outcome
measure.111 The ongoing ADAPT trial evaluates the effect of super-
vised exercise, individualized dietary counseling, and reduced seden-
tary behavior, as tracked by actigraphy, on the rate of progression of
DPN.112
Bariatric surgery is also a potential intervention for DPN. An
ongoing randomized trial is evaluating the effect of bariatric surgery
and high intensive interval training, either in combination or alone, on
F IGURE 2 Therapeutic targets identified by dietary intervention and inflammatory pathway studies. Molecular targets were identified in pre-
clinical studies using murine models of dyslipidemia and DPN. Dietary intervention with MUFA supplementation reverses DPN progression
potentially through the sequestration of SFAs into LDs in sensory neurons. Dietary reversal from a high-fat diet to a standard diet reduces the
level of SFAs in sensory neurons. Subsequent to both dietary intervention paradigms, reduced levels of acylcarnitine improves mitochondrial
function and prevent apoptosis. Similarly, stimulation of PGC-1α, PPARγ, and LXR transcription factors by pioglitazone activates FFA β-oxidation,
improving mitochondrial function and nerve function. Pioglitazone and Acipimox both inhibit NF-κB activation of pro-inflammatory pathways.
The reduction in pro-inflammatory TNF-α, IL-6, COX-2, and ROS production prevents downstream mitochondrial dysfunction and sensory
neuron apoptosis. DPN, diabetic peripheral neuropathy; FFA, free fatty acid; ROS, reactive oxygen species; SFA, saturated fatty acid
80 STINO ET AL.
DPN (NCT03617185). A previous prospective 6-month cohort study
assessing the impact of Roux-en-Y gastric bypass on the development
of DPN in T2DM patients showed an improvement in neuropathy
scores.113 As for drug therapies, the Topiramate as a Disease Altering
Therapy for Cryptogenic Neuropathy (TopCSPN) study is a multi-cen-
ter, placebo-controlled, randomized trial in the United States that just
completed enrollment, which aims to determine if topiramate can alter
the natural history of MetS neuropathy (NCT02878798). Both trials
employ IENFD as the primary outcome measure.
It is unknown whether single-target or multi-target interven-
tions are needed to attain full disease-modifying efficacy. Pathway
cross-talk perturbation modeling has been employed to identify
connectivity changes induced by DPN and potential therapeutic
interventions, and offers a novel approach to DPN disease modifica-
tion strategy.114
5 | CONCLUSION
In this review, we explored modern concepts in our understanding of
DPN, and how this can guide a more informed and precise approach
to disease modifying therapy in the future. Despite the ubiquity of
DPN and its economic cost, no approved disease modifying therapies
exist, although exercise, dietary restriction, and bariatric surgery show
some early favorable findings. Central to this understanding is a reali-
zation that T1DM and T2DM pathomechanisms are intrinsically dif-
ferent, with the type 2 DPN paradigm being much more responsive to
interventions aimed at MetS rather than hyperglycemia. Through a
greater appreciation of DPN pathomechanisms, particularly as it per-
tains to T2DM and MetS, the potential for disease modifying thera-
pies remains promising.
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